Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kalaris Therapeutics ( (KLRS) ) has provided an announcement.
Kalaris Therapeutics, Inc. has announced that its 2025 annual meeting of stockholders will be held on August 12, 2025, a change of more than 30 days from the previous year’s meeting. Stockholders are required to submit proposals by June 30, 2025, to be included in the proxy materials, and must comply with the company’s by-laws and SEC rules. This adjustment in the meeting schedule signifies a shift in the company’s operational timeline, potentially impacting stakeholder engagement and decision-making processes.
The most recent analyst rating on (KLRS) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Kalaris Therapeutics stock, see the KLRS Stock Forecast page.
Spark’s Take on KLRS Stock
According to Spark, TipRanks’ AI Analyst, KLRS is a Underperform.
AlloVir’s stock is heavily impacted by its financial performance challenges, including consistent net losses and negative cash flow. Technical analysis also indicates a bearish trend, with prices below key moving averages and weak momentum indicators. The negative P/E ratio and absence of dividend yield further highlight valuation concerns, making it a less attractive investment at this time.
To see Spark’s full report on KLRS stock, click here.
More about Kalaris Therapeutics
Average Trading Volume: 48,458
Technical Sentiment Signal: Sell
Current Market Cap: $43.02M
See more insights into KLRS stock on TipRanks’ Stock Analysis page.